US-based patient monitoring technology developer Glooko received $30m in series D funding yesterday from investors including drug producer Novo Nordisk, diabetes equipment provider Insulet and medical research and care provider Mayo Clinic.
Investment manager Health Catalyst Capital led the round, which also featured venture capital firm Canaan and growth equity firm Georgian.
Glooko combines telehealth technology and data sourced from a range of medical devices such as blood-glucose meters, insulin pumps and activity trackers to remotely connect diabetes patients with healthcare professionals who can get a vivid picture of their condition.
The company had previously raised a total of $71m, as of a $35m series C round in 2017 that included Imsulet, Mayo Clinic, Georgian, Canaan Partners, medical device maker Medtronic and Samsung Next, a subsidiary of electronics producer Samsung, as well as VC firm Social Capital.
Medtronic, Social Capital, Canaan and Samsung vehicle Samsung Ventures were all among Glooko’s earlier investors, as were Lifeforce Ventures, Xtreme Labs and various individuals.
